Annexon presented results from its completed Phase 3 trial of ANX005, a C1q-targeted immunotherapy for Guillain-Barré Syndrome (GBS). The trial showed a highly statistically significant effect on the primary endpoint, with early, robust, and durable treatment effects. The single-dose administration was well-tolerated with mostly mild to moderate adverse events.